Literature DB >> 7686692

Activation of protein C and its distribution between its inhibitors, protein C inhibitor, alpha 1-antitrypsin and alpha 2-macroglobulin, in patients with disseminated intravascular coagulation.

M F Scully1, C H Toh, H Hoogendoorn, R P Manuel, M E Nesheim, S Solymoss, A R Giles.   

Abstract

Activation and inactivation of protein C during the clinical course of disseminated intravascular coagulation (DIC) was studied in three patients by qualitative (Western blotting) and quantitative (ELISA) analysis and the intensity of procoagulant activity monitored by the measurement of thrombin and factor Xa antithrombin III complexes. In one patient, inhibitor complexes of APC with protein C inhibitor (PCI) and alpha 1-antitrypsin (alpha 1-AT) were observed and the latter predominated at presentation. Both disappeared during the development of remission but the loss of alpha 1-AT complexes preceded PCI complexes which on Western blotting appeared to increase in intensity prior to disappearance. The two other patients bled to death from uncontrollable haemorrhage. In both cases, APC/inhibitor complexes with alpha 2-macroglobulin (alpha 2-M) in addition to PCI and alpha 1-AT were detected and persisted until death. Although PCI appeared to be the primary inhibitor in all three cases, alpha 1-antitrypsin and particularly alpha 2-macroglobulin appeared to assume greater roles in the two fatal cases. These data are similar to previous findings in an experimental animal model of DIC that suggested that alpha 2-macroglobulin and alpha 1-antitrypsin become more important inhibitors of APC as the primary inhibitor PCI is consumed in the face of a sustained procoagulant challenge.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686692

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Engineering the proteolytic specificity of activated protein C improves its pharmacological properties.

Authors:  David T Berg; Bruce Gerlitz; Jing Shang; Tommy Smith; Paula Santa; Mark A Richardson; Ken D Kurz; Brian W Grinnell; Ken Mace; Bryan E Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-01       Impact factor: 11.205

2.  α2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:α2M Levels Are Associated with Venous Thromboembolism.

Authors:  Laura Martos; Luis Andrés Ramón; Julia Oto; Álvaro Fernández-Pardo; Santiago Bonanad; Ana Rosa Cid; Andras Gruber; John H Griffin; Francisco España; Silvia Navarro; Pilar Medina
Journal:  Thromb Haemost       Date:  2018-02-15       Impact factor: 5.249

3.  The 2.8 A crystal structure of Gla-domainless activated protein C.

Authors:  T Mather; V Oganessyan; P Hof; R Huber; S Foundling; C Esmon; W Bode
Journal:  EMBO J       Date:  1996-12-16       Impact factor: 11.598

4.  Drotrecogin alfa (activated).

Authors:  Katherine A Lyseng-Williamson; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Studies of thrombin-induced proteoglycan release in the degradation of human and bovine cartilage.

Authors:  E Furmaniak-Kazmierczak; T D Cooke; R Manuel; A Scudamore; H Hoogendorn; A R Giles; M Nesheim
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

Review 6.  [Role of the innate immune response in sepsis].

Authors:  C Hörner; A Bouchon; A Bierhaus; P P Nawroth; E Martin; H J Bardenheuer; M A Weigand
Journal:  Anaesthesist       Date:  2004-01       Impact factor: 1.041

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.